United Therapeutics Corporation Q3 2025 Earnings Recap

UTHR Q3 2025 October 29, 2025

Get alerts when UTHR reports next quarter

United Therapeutics Corporation reported a record revenue of $800 million for Q3 2025, reflecting a 7% year-over-year growth, driven by strong demand for Tyvaso and Orenitram and significant advancements in its clinical pipeline.

Earnings Per Share Beat

$7.16 vs $6.89 est.

+3.9% surprise

Revenue Miss

799500000 vs 814800920 est.

-1.9% surprise

Market Reaction

1-Day +9.63%

5-Day +5.61%

30-Day +14.32%

See UTHR alongside your other holdings

Add to your portfolio — free

Key Takeaways

Fully enrolled three Phase III trials, achieving best-ever results for pulmonary fibrosis, indicating strong potential to expand patient treatment.
Launched new Tyvaso DPI 80-microgram cartridges to enhance dosing convenience and capture additional market share in the pulmonary hypertension space.
Significant progress in securing favorable payer coverage decisions, reinforcing Tyvaso DPI's competitive positioning in the market.
Confidently projecting a $4 billion revenue run rate by 2027, backed by ongoing product innovations and market demand.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit UTHR on AllInvestView.

Previous Q2 2025

Next Q1 2026